
Europe Monkeypox Testing Market - Industry Outlook and Forecast 2023-2025
Description
Europe Monkeypox Testing Market - Industry Outlook and Forecast 2023-2025
The Europe monkeypox testing market was valued at USD 18,330.00 thousand in 2022 and is expected to reach USD 56.10 thousand by 2025.
KEY MARKET INSIGHTS
The growing product launches of lateral flow assay kits are expected to create lucrative opportunities for the Europe monkeypox testing market growth. Lateral flow assay is presently not preferred for monkeypox detection in the region because it may give false positive and negative results and because of its high cost. A number of rapid antibody and antigen test kits has been developed. Nanjing Synthgene Medical Technology, a China-based biomedical company, offers CE-certified rapid antibody and antigen tests at USD 1,253 and USD 438, respectively. In contrast, its MPXV Detection Kit (RT-PCR) costs around USD 144 with 24 tests, which means about USD 6 for each test.
Segmentation By Type
Segmentation By End-User
Since the time of vaccine approval, the region has been ramping up to supply vaccine doses to every country dealing with the highest number of cases. Vaccine administration and contact tracing have rapidly increased in Spain, the second country after the US, with the highest number of confirmed cases since June 2022. On 20th October 2022, National Health Service (NHS) launched a new online vaccine site finder to make it easy for eligible people to vaccinate.
REGIONAL ANALYSIS
In 2022, EU-5 accounted for the largest share of 77.71% in the Europe monkeypox testing market. In EU-5, Spain accounts for the highest revenue share, followed by France, UK, Germany, and Italy, which can be attributed to increasing cases, and increased testing. More than 98% of cases are identified in men who have sex with men in EU-5. The Netherlands is vaccinating high-risk people against MPX using two doses of the Imvanex smallpox vaccine. Until 3rd August 2022, 1,976 people in the Netherlands received a preventive vaccination against the MPXV.
In Berlin, Germany, vaccinations against the viral infection had begun in mid-July. In July, The Standing Commission on Vaccination (Stiko) recommended this for certain groups and people who have had close contact with infected persons. It sees an increased risk of infection, particularly among men who have same-sex sexual contact with changing partners. According to the Senate Department for Health, demand for the MPX vaccine is very high in Berlin; however, the vaccine is still in very short supply. The shortage in vaccine supply has increased the chances of spreading MPX, which implicitly increases the possibilities of the Europe monkeypox testing market growth. However, in the future, the growing number of vaccinations for monkeypox may hinder the growth of the MPX testing market. In addition, as the currently authorized vaccine, Imvanex is not authorized for children and pregnant women, the growth of MPX testing still holds growth opportunities during the forecast period. Also, an increase in risky behavior may cause a resurgence of the virus that may keep the opportunity for MPX testing market demand.
Segmentation By Region
How big is the Europe monkeypox testing market?
What is the projected growth rate of the Europe monkeypox testing market during the forecast period?
What are the growing trends in the Europe monkeypox testing market?
Which region holds the largest Europe monkeypox testing market share?
Which are the key players in the Europe monkeypox testing market?
The Europe monkeypox testing market was valued at USD 18,330.00 thousand in 2022 and is expected to reach USD 56.10 thousand by 2025.
KEY MARKET INSIGHTS
- Syndromic tests for monkeypox detection are expected to witness strong growth because they can distinguish monkeypox from other harmful diseases, allowing for easier treatment. On 25th May 2022, Roche and its subsidiary TIB Molbiol announced that they had developed a unique LightMix Modular Virus kit that simultaneously detects orthopoxvirus and offers information on whether an MPXV is present or not, including all MPXV from both the West African and Central African forms of the virus.
- Rapid tests in the Europe monkeypox testing market are also expected to witness strong growth due to their rapid results and increasing consumer preference.
- Demand for MPXV testing kits is expected to decline during the forecast as the cases can be seen declining due to increased surveillance, contact tracing, and increasing vaccination across Europe.
- In July 2022, ELITechGroup, a France-based privately held manufacturer and distributor of IVD equipment, strategically partnered with Jiangsu Bioperfectus Technologies for monkeypox virus testing across Europe.
- In June 2022, Eurobio Scientific launched a CE-marked monkeypox screening test available for hospital use in France.
- On 8th June 2022, altona Diagnostics, a medical diagnostic company headquartered in Germany, announced the launch of the RealStar Zoonotic Orthopoxvirus PCR Kit 1.0, a real-time RT-PCR based reagent system for the detection of zoonotic (non-variola) Orthopoxvirus species-specific DNA – including MPVX DNA of the Central and West African strains.
- On 27th June 2022, Cepheid collaborated with the UK-based global molecular diagnostics company BioGX and announced a partnership between the two companies to provide a PCR test for MPX that will run on the GeneXpert system.
- In July, the altona Diagnostics company launched another monkeypox virus detection kit, Flexstar Monkeypox virus PCR Detection Mix 1.5, for research purposes.
- Bioactiva Diagnostica is another Germany-based company that offers PCR kits for monkeypox virus detection.
The growing product launches of lateral flow assay kits are expected to create lucrative opportunities for the Europe monkeypox testing market growth. Lateral flow assay is presently not preferred for monkeypox detection in the region because it may give false positive and negative results and because of its high cost. A number of rapid antibody and antigen test kits has been developed. Nanjing Synthgene Medical Technology, a China-based biomedical company, offers CE-certified rapid antibody and antigen tests at USD 1,253 and USD 438, respectively. In contrast, its MPXV Detection Kit (RT-PCR) costs around USD 144 with 24 tests, which means about USD 6 for each test.
Segmentation By Type
- PCR
- Lateral Flow Assay
- Others
Segmentation By End-User
- Laboratories
- Hospitals & Clinics
- Others
Since the time of vaccine approval, the region has been ramping up to supply vaccine doses to every country dealing with the highest number of cases. Vaccine administration and contact tracing have rapidly increased in Spain, the second country after the US, with the highest number of confirmed cases since June 2022. On 20th October 2022, National Health Service (NHS) launched a new online vaccine site finder to make it easy for eligible people to vaccinate.
REGIONAL ANALYSIS
In 2022, EU-5 accounted for the largest share of 77.71% in the Europe monkeypox testing market. In EU-5, Spain accounts for the highest revenue share, followed by France, UK, Germany, and Italy, which can be attributed to increasing cases, and increased testing. More than 98% of cases are identified in men who have sex with men in EU-5. The Netherlands is vaccinating high-risk people against MPX using two doses of the Imvanex smallpox vaccine. Until 3rd August 2022, 1,976 people in the Netherlands received a preventive vaccination against the MPXV.
In Berlin, Germany, vaccinations against the viral infection had begun in mid-July. In July, The Standing Commission on Vaccination (Stiko) recommended this for certain groups and people who have had close contact with infected persons. It sees an increased risk of infection, particularly among men who have same-sex sexual contact with changing partners. According to the Senate Department for Health, demand for the MPX vaccine is very high in Berlin; however, the vaccine is still in very short supply. The shortage in vaccine supply has increased the chances of spreading MPX, which implicitly increases the possibilities of the Europe monkeypox testing market growth. However, in the future, the growing number of vaccinations for monkeypox may hinder the growth of the MPX testing market. In addition, as the currently authorized vaccine, Imvanex is not authorized for children and pregnant women, the growth of MPX testing still holds growth opportunities during the forecast period. Also, an increase in risky behavior may cause a resurgence of the virus that may keep the opportunity for MPX testing market demand.
Segmentation By Region
- Europe
- EU-5
- Spain
- France
- UK
- Germany
- Italy
- Central, Eastern, and Southern Europe
- Netherlands
- Portugal
- Switzerland
- Nordic
- Sweden
- Denmark
- Hoffmann-La Roche
- Qiagen
- altona Diagnostics
- Autobio
- Applied DNA Sciences
- Aurora Biomed
- bioactiva diagnostica
- Beijing Hotgen Biotech
- BioGX
- CERTEST BIOTEC
- Creative Biogene
- CorDx
- CLONIT
- Eurobio Scientific
- FireGene
- GenScript
- Guangzhou Pluslife Biotech
- JOYSBIO (Tianjin) Biotechnology
- Nanjing Synthgene Medical Technology
- RayBiotech Life
- Sansure Biotech
- Virax Biolabs
- Wondfo
- Shanghai Biogerm Medical Technology
How big is the Europe monkeypox testing market?
What is the projected growth rate of the Europe monkeypox testing market during the forecast period?
What are the growing trends in the Europe monkeypox testing market?
Which region holds the largest Europe monkeypox testing market share?
Which are the key players in the Europe monkeypox testing market?
Table of Contents
159 Pages
- 1 RESEARCH METHODOLOGY
- 2 RESEARCH OBJECTIVES
- 3 RESEARCH PROCESS
- 4 SCOPE & COVERAGE
- 4.1 MARKET DEFINITION
- 4.1.1 INCLUSIONS
- 4.1.2 EXCLUSIONS
- 4.1.3 MARKET ESTIMATION CAVEATS
- 4.2 BASE YEAR
- 4.3 SCOPE OF THE STUDY
- 4.3.1 MARKET SEGMENTATION BY TYPE
- 4.3.2 MARKET SEGMENTATION BY END-USER
- 4.3.3 MARKET SEGMENTATION BY GEOGRAPHY
- 5 REPORT ASSUMPTIONS & CAVEATS
- 5.1 KEY CAVEATS
- 5.2 CURRENCY CONVERSION
- 5.3 MARKET DERIVATION
- 6 PREMIUM INSIGHTS
- 6.1 OVERVIEW
- 7 MARKET AT A GLANCE
- 8 INTRODUCTION
- 8.1 OVERVIEW
- 9 MARKET OPPORTUNITIES & TRENDS
- 9.1 DEVELOPMENT OF RAPID TESTING METHODS
- 9.2 ADVANCES IN PCR TECHNOLOGY
- 9.3 VENDOR COLLABORATIONS
- 10 MARKET GROWTH ENABLERS
- 10.1 INCREASED GOVERNMENT SURVEILLANCE
- 10.2 EASE OF REGULATIONS FOR PRODUCT APPROVALS
- 10.3 INCREASED PRODUCT LAUNCHES
- 11 MARKET RESTRAINTS
- 11.1 DECLINE IN MPX CASES
- 11.2 MPX VACCINE APPROVAL & ACCESS
- 11.3 FALSE MPX TEST RESULTS
- 12 MARKET LANDSCAPE
- 12.1 MARKET OVERVIEW
- 12.1.1 INSIGHTS BY TYPE
- 12.1.2 INSIGHTS BY END-USER
- 12.1.3 INSIGHTS BY GEOGRAPHY
- 12.2 FIVE FORCES ANALYSIS
- 12.2.1 THREAT OF NEW ENTRANTS
- 12.2.2 BARGAINING POWER OF SUPPLIERS
- 12.2.3 BARGAINING POWER OF BUYERS
- 12.2.4 THREAT OF SUBSTITUTES
- 12.2.5 COMPETITIVE RIVALRY
- 13 TEST TYPE
- 13.1 MARKET SNAPSHOT & GROWTH ENGINE
- 13.2 MARKET OVERVIEW
- 13.3 PCR
- 13.3.1 MARKET OVERVIEW
- 13.3.2 MARKET SIZE & FORECAST
- 13.4 LATERAL FLOW ASSAYS
- 13.4.1 MARKET OVERVIEW
- 13.4.2 MARKET SIZE & FORECAST
- 13.5 OTHERS
- 13.5.1 MARKET OVERVIEW
- 13.5.2 MARKET SIZE & FORECAST
- 14 END-USER
- 14.1 MARKET SNAPSHOT & GROWTH ENGINE
- 14.2 MARKET OVERVIEW
- 14.3 LABORATORIES
- 14.3.1 MARKET OVERVIEW
- 14.3.2 MARKET SIZE & FORECAST
- 14.4 HOSPITALS & CLINICS
- 14.4.1 MARKET OVERVIEW
- 14.4.2 MARKET SIZE & FORECAST
- 14.5 OTHERS
- 14.5.1 MARKET OVERVIEW
- 14.5.2 MARKET SIZE & FORECAST
- 15 GEOGRAPHY
- 15.1 MARKET SNAPSHOT & GROWTH ENGINE
- 15.2 MARKET OVERVIEW
- 16 EU-5
- 16.1 MARKET OVERVIEW
- 16.2 MARKET SIZE & FORECAST
- 16.3 KEY COUNTRIES
- 16.3.1 SPAIN: MARKET SIZE & FORECAST
- 16.3.2 FRANCE: MARKET SIZE & FORECAST
- 16.3.3 UK: MARKET SIZE & FORECAST
- 16.3.4 GERMANY: MARKET SIZE & FORECAST
- 16.3.5 ITALY: MARKET SIZE & FORECAST
- 17 CENTRAL, EASTERN & SOUTHERN EUROPE
- 17.1 MARKET OVERVIEW
- 17.2 MARKET SIZE & FORECAST
- 17.3 KEY COUNTRIES
- 17.3.1 NETHERLANDS: MARKET SIZE & FORECAST
- 17.3.2 PORTUGAL: MARKET SIZE & FORECAST
- 17.3.3 SWITZERLAND: MARKET SIZE & FORECAST
- 18 NORDICS
- 18.1 MARKET OVERVIEW
- 18.2 MARKET SIZE & FORECAST
- 18.3 KEY COUNTRIES
- 18.3.1 SWEDEN: MARKET SIZE & FORECAST
- 18.3.2 DENMARK: MARKET SIZE & FORECAST
- 19 COMPETITIVE LANDSCAPE
- 19.1 COMPETITION OVERVIEW
- 19.2 MARKET SHARE ANALYSIS
- 19.2.1 F. HOFFMANN-LA ROCHE
- 19.2.2 QIAGEN
- 20 KEY COMPANY PROFILES
- 20.1 F. HOFFMANN-LA ROCHE
- 20.1.1 BUSINESS OVERVIEW
- 20.1.2 PRODUCT OFFERINGS
- 20.1.3 KEY STRATEGIES
- 20.1.4 KEY STRENGTHS
- 20.1.5 KEY OPPORTUNITIES
- 20.2 QIAGEN
- 20.2.1 BUSINESS OVERVIEW
- 20.2.2 PRODUCT OFFERINGS
- 20.2.3 KEY STRATEGIES
- 20.2.4 KEY STRENGTHS
- 20.2.5 KEY OPPORTUNITIES
- 21 OTHER PROMINENT VENDORS
- 21.1 ALTONA DIAGNOSTICS
- 21.1.1 BUSINESS OVERVIEW
- 21.1.2 PRODUCT OFFERINGS
- 21.2 AUTOBIO
- 21.2.1 BUSINESS OVERVIEW
- 21.2.2 PRODUCT OFFERINGS
- 21.3 APPLIED DNA SCIENCES
- 21.3.1 BUSINESS OVERVIEW
- 21.3.2 PRODUCT OFFERINGS
- 21.4 AURORA BIOMED
- 21.4.1 BUSINESS OVERVIEW
- 21.4.2 PRODUCT OFFERINGS
- 21.5 BIOACTIVA DIAGNOSTICA
- 21.5.1 BUSINESS OVERVIEW
- 21.5.2 PRODUCT OFFERINGS
- 21.6 BEIJING HOTGEN BIOTECH
- 21.6.1 BUSINESS OVERVIEW
- 21.6.2 PRODUCT OFFERINGS
- 21.7 BIOGX
- 21.7.1 BUSINESS OVERVIEW
- 21.7.2 PRODUCT OFFERINGS
- 21.8 CERTEST BIOTEC
- 21.8.1 BUSINESS OVERVIEW
- 21.8.2 PRODUCT OFFERINGS
- 21.9 CREATIVE BIOGENE
- 21.9.1 BUSINESS OVERVIEW
- 21.9.2 PRODUCT OFFERINGS
- 21.10 CORDX
- 21.10.1 BUSINESS OVERVIEW
- 21.10.2 PRODUCT OFFERINGS
- 21.11 CLONIT
- 21.11.1 BUSINESS OVERVIEW
- 21.11.2 PRODUCT OFFERINGS
- 21.12 EUROBIO SCIENTIFIC
- 21.12.1 BUSINESS OVERVIEW
- 21.12.2 PRODUCT OFFERINGS
- 21.13 FIREGENE
- 21.13.1 BUSINESS OVERVIEW
- 21.13.2 PRODUCT OFFERINGS
- 21.14 GENSCRIPT
- 21.14.1 BUSINESS OVERVIEW
- 21.14.2 PRODUCT OFFERINGS
- 21.15 GUANGZHOU PLUSLIFE BIOTECH
- 21.15.1 BUSINESS OVERVIEW
- 21.15.2 PRODUCT OFFERINGS
- 21.16 JOYSBIO (TIANJIN) BIOTECHNOLOGY
- 21.16.1 BUSINESS OVERVIEW
- 21.16.2 PRODUCT OFFERINGS
- 21.17 NANJING SYNTHGENE MEDICAL TECHNOLOGY
- 21.17.1 BUSINESS OVERVIEW
- 21.17.2 PRODUCT OFFERINGS
- 21.18 RAYBIOTECH LIFE
- 21.18.1 BUSINESS OVERVIEW
- 21.18.2 PRODUCT OFFERINGS
- 21.19 SANSURE BIOTECH
- 21.19.1 BUSINESS OVERVIEW
- 21.19.2 PRODUCT OFFERINGS
- 21.20 VIRAX BIOLABS
- 21.20.1 BUSINESS OVERVIEW
- 21.20.2 PRODUCT OFFERINGS
- 21.21 WONDFO
- 21.21.1 BUSINESS OVERVIEW
- 21.21.2 PRODUCT OFFERINGS
- 21.22 SHANGHAI BIOGERM MEDICAL TECHNOLOGY
- 21.22.1 BUSINESS OVERVIEW
- 21.22.2 PRODUCT OFFERINGS
- 22 REPORT SUMMARY
- 22.1 KEY TAKEAWAYS
- 22.2 STRATEGIC RECOMMENDATIONS
- 23 QUANTITATIVE SUMMARY
- 23.1 MARKET BY GEOGRAPHY
- 23.2 MARKET BY TYPE
- 23.3 MARKET BY END-USER
- 24 APPENDIX
- 24.1 ABBREVIATIONS
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.